About Eyevance
Eyevance was founded in 2017 and is headquartered in Fort Worth, United States. Ophthalmic therapy products are developed by the company, with a focus on treatments for the ocular surface and anterior segment. Operations are centered in the biopharmaceutical sector, where specialized eye care solutions are provided to address common anterior eye conditions. Geographic activities are primarily based in the United States, supporting healthcare providers through targeted therapeutic options.
- Headquarter Fort Worth, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Acquired by
Santen Pharmaceuticals
(Sep 16, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Eyevance
Detailed funding history for Eyevance
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Eyevance
Eyevance has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Santen Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pharmaceutical products for ophthalmology and rheumatology diseases are manufactured.
|
Locked | Locked | Locked |
Investor details for Eyevance
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Eyevance
Investment portfolio details for Eyevance
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Eyevance
Detailed financials for Eyevance
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Eyevance Comparisons
Peer comparison for Eyevance
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Eyevance
Detailed competitors of Eyevance
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Eyevance
Complete news archive for Eyevance
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Eyevance
Eyevance was founded in 2017.
Eyevance is headquartered in Fort Worth, United States. It is registered at Fort Worth, Texas, United States.
Eyevance was founded in 2017 and is headquartered in Fort Worth, United States. Ophthalmic therapy products are developed by the company, with a focus on treatments for the ocular surface and anterior segment. Operations are centered in the biopharmaceutical sector, where specialized eye care solutions are provided to address common anterior eye conditions. Geographic activities are primarily based in the United States, supporting healthcare providers through targeted therapeutic options.
Eyevance has 1 investor. Key investors include Santen Pharmaceuticals.